215 related articles for article (PubMed ID: 29935731)
41. Ethical concerns regarding private equity in Right to Try in the USA.
Lee SW; Hurst DJ
Lancet Oncol; 2020 Oct; 21(10):1260-1262. PubMed ID: 33002434
[No Abstract] [Full Text] [Related]
42. Characterizing expanded access and compassionate use programs for experimental drugs.
Miller JE; Ross JS; Moch KI; Caplan AL
BMC Res Notes; 2017 Jul; 10(1):350. PubMed ID: 28754150
[TBL] [Abstract][Full Text] [Related]
43. Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines.
Pinxten W; Nys H; Dierickx K
J Med Ethics; 2010 Dec; 36(12):791-4. PubMed ID: 20852303
[TBL] [Abstract][Full Text] [Related]
44. Single-patient expanded access: A primer for pharmacists.
Smith AJF; Redic KA
Am J Health Syst Pharm; 2022 Nov; 79(23):2118-2127. PubMed ID: 36056791
[TBL] [Abstract][Full Text] [Related]
45. Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam.
Jacob JA
JAMA; 2015 Aug; 314(8):758-60. PubMed ID: 26244653
[No Abstract] [Full Text] [Related]
46. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs.
Chapman CR; Eckman J; Bateman-House AS
Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412
[TBL] [Abstract][Full Text] [Related]
47. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z
PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568
[TBL] [Abstract][Full Text] [Related]
48. Principled compassion.
Nat Med; 2014 Dec; 20(12):1355. PubMed ID: 25473904
[TBL] [Abstract][Full Text] [Related]
49. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis.
Horsburgh CR; Haxaire-Theeuwes M; Lienhardt C; Wingfield C; McNeeley D; Pyne-Mercier L; Keshavjee S; Varaine F; ;
Int J Tuberc Lung Dis; 2013 Feb; 17(2):146-52. PubMed ID: 23211610
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022.
Wu J; Yang Y; Yu J; Qiao L; Zuo W; Zhang B
Orphanet J Rare Dis; 2023 Nov; 18(1):368. PubMed ID: 38017575
[TBL] [Abstract][Full Text] [Related]
51. Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis.
Vermeulen SF; Hordijk M; Visser RJ; Bunnik EM
J Law Med Ethics; 2023; 51(1):172-180. PubMed ID: 37226748
[TBL] [Abstract][Full Text] [Related]
52. Access to experimental medicines for TB: ethical and human rights considerations.
Dagron S; Chakhaia T; González-Angulo L; Hermanns S; Skrahina A; Wallace AEM
Int J Tuberc Lung Dis; 2020 May; 24(5):38-43. PubMed ID: 32553042
[TBL] [Abstract][Full Text] [Related]
53. Expanded Access Allows for Compassionate Use of Investigational Cancer Drugs.
Miller D
ONS Connect; 2015 Jun; 30(2):47. PubMed ID: 26137830
[No Abstract] [Full Text] [Related]
54. Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021.
Maeda H; Uchida M; Kusano M; Tsukamoto K; Yamanoi M
Clin Pharmacol Ther; 2022 Oct; 112(4):817-823. PubMed ID: 35569010
[TBL] [Abstract][Full Text] [Related]
55. Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework.
Mehrotra N; Manchikanti P
Med Law Rev; 2024 Feb; 32(1):20-41. PubMed ID: 37616571
[TBL] [Abstract][Full Text] [Related]
56. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
57. Single-Patient Expanded Access Requests: IRB Professionals' Experiences and Perspectives.
Chapman CR; Shearston JA; Folkers KM; Redman BK; Caplan A; Bateman-House A
AJOB Empir Bioeth; 2019; 10(2):88-99. PubMed ID: 30964737
[TBL] [Abstract][Full Text] [Related]
58. Ethics framework for treatment use of investigational drugs.
Borysowski J; Górski A
BMC Med Ethics; 2020 Nov; 21(1):116. PubMed ID: 33208140
[TBL] [Abstract][Full Text] [Related]
59. Prevalence of Publicly Available Expanded Access Policies.
Jung E; Zettler PJ; Kesselheim AS
Clin Pharmacol Ther; 2018 Nov; 104(5):1016-1021. PubMed ID: 29271014
[TBL] [Abstract][Full Text] [Related]
60. Right-to-Try Investigational Therapies for Incurable Disorders.
Simmons Z
Continuum (Minneap Minn); 2017 Oct; 23(5, Peripheral Nerve and Motor Neuron Disorders):1451-1457. PubMed ID: 28968371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
